ASCO 2026: Five-Year Data Support Nivolumab Plus Relatlimab in Advanced Melanoma

Five-year results from the RELATIVITY-047 trial were presented by Hussein A. Tawbi, MD, PhD, Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA, at the ASCO 2026 Congress. He discusses the long-term efficacy and safety of nivolumab plus relatlimab in previously untreated advanced melanoma, including durable progression-free survival, overall survival outcomes, and emerging insights into mechanisms of response and resistance.